Log in to save to my catalogue

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5228595

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Fourteen of 16 patients with metastatic, castration-resistant prostate cancer and genetic defects in repair of DNA damage had a response to the PARP inhibitor olaparib. Anemia and fatigue were the major toxic effects.
Prostate cancer is the most common cancer in men and the sixth leading cause of death from cancer among men throughout the world....

Alternative Titles

Full title

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5228595

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5228595

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1506859

How to access this item